Background {#Sec1}
==========

Different radiotherapy techniques and fractionation regimes are currently used for the treatment of localized prostate cancer. Conventionally fractionated intensity modulated radiotherapy (IMRT) is the most frequently applied treatment modality for prostate cancer \[[@CR1]--[@CR4]\]. IMRT can be performed either by static ("step-and-shoot" (SS), Sliding Window (SW)) or rotational approaches (helical tomotherapy (HT) or Volumetric Modulated Arc Therapy (Rapid Arc, RA). Intensity modulated proton therapy (IMPT) is also a well-known treatment modality for localized prostate cancer and is more likely to spare the organs at risk (OAR) due to steep dose gradients outside of the Bragg peak \[[@CR5]--[@CR9]\]. All of these techniques are capable of achieving treatment plans with high conformity, reducing the dose delivered to the surrounding healthy tissue and, consequently, treatment-related toxicities, especially the risk of secondary malignancy. To date there is no consensus on the "optimal overall" treatment mode \[[@CR10], [@CR11]\]. In this study, a statistical analysis of dosimetric parameters between HT, SW, RA and IMPT providing conventionally fractionated radiotherapy was evaluated. Similar dose objectives for PTV and OAR were used in the radiation planning for all techniques. The dosimetric indices were assessed according to the criteria of the International Commission on Radiation Units and Measurements (ICRU) Report 83 \[[@CR12]\].

Material and methods {#Sec2}
====================

Treatment plans were generated for 20 randomly selected patients with low-risk prostate cancer who received definitive HT. The databases of thin-cut 3 mm CT scans were fused with those of 1.5 T MRI scans. The target dose was calculated to be 79.2Gy. According to ICRU Report 83, at least 95 % of the prescribed dose should cover 98 % of the prostate volume (D98 %) and a maximum of 107 % of the prescribed dose should cover 2 % of the prostate volume (D2 %) \[[@CR12]\]. Both dose objectives for PTV and OAR, as well as multiple specific physical planning support structures used for treatment planning are presented in a "Additional file [1](#MOESM1){ref-type="media"}". Seven-field IMRT plans using the SW technique were created on the Eclipse™ 10 treatment planning system \[Varian Medical Systems, Palo Alto USA\]. All plans were generated for the Varian True Beam linear accelerator (LINAC) using beam energies of 15MV photons and beam angles of 0, 51, 102, 153, 204, 255 and 306°. The RA plans were created using the same treatment planning system as for SW. Two incomplete arcs from 200 to 160°, intended to protect the posterior rectum wall, were used. The plans were created using 15MV photons with a 0.5 cm leaf width. A maximum dose rate of 600 MU/min and MLC motion of 2.5 cm/s were applied. The MLC-leakage was at 1.8 %. The HT plans were assessed using Tomo Planning System Version 5 (Accuray® Inc., Sunnyvale, USA). The plans were created for the High Art HDII HT system that uses a helical slice 6MV photon beam modulated by 64 binary multileaf collimators. The IMPT plans were generated using the Eclipse™ 10 treatment planning system (Varian Medical Systems, Palo Alto USA). Each plan consisted of two opposing right and left lateral beams (gantry angles of 90° and 270°) with incident proton beam energies in the 100--235 MeV range. To create homogeneous target coverage, a multi-field optimization was used with minimum spot MUs of 0.4.

The clinical target volume (CTV) and planning target volume (PTV) were defined according to the Radiation Therapy Oncology Group (RTOG) 0521 protocol \[[@CR13]\]. The CTV included the prostate and did not involve the seminal vesicles. A 3 mm margin in the dorsal direction and 5 mm margin in all other directions was added to delineate the PTV. The dose-volume objectives met the criteria for rectum and urinary bladder set out by the Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) reports and for femoral heads established by the RTOG Prostate Group Consensus 2009 (Table [1](#Tab1){ref-type="table"}) \[[@CR13]--[@CR15]\]. The following dosimetric indices were assessed: V10, V30, V50, V70 (defined as the percentage of organ volume receiving given radiation dose), Dmean, Dmax and D1cc for rectum and bladder, as well as V50 and D1ccm for femoral heads. A comparison of each patient was made using a scoring system that compared D2 %, D98 % and V95 values. The indices for the 20 patients were averaged to assess the advantages and disadvantages in PTV coverage and OAR sparing of the various radiation techniques.Table 1Organ at risk dose objectivesOrganDoseVolume (in % or in ccm as absolute volume for femoral heads)Rectum \[[@CR14]\]10Gy--^a^30Gy\<60 %50Gy\<50 %60Gy\<35 %65Gy\<25 %70Gy\<20 %75Gy\<15 %Urinary bladder \[[@CR15]\]10Gy--^a^30Gy--^a^50Gy\<60 %65Gy\<50 %70Gy\<35 %75Gy\<25 %Femoral heads \[[@CR13]\]50Gy\<5 %40Gy≤1ccmAbbreviations: ^a^-the dose-volume limit is not defined in the QUANTEC reports

Based on the recommendations of the ICRU 83 reports and several clinical studies, specific conformal indices were used to describe the dose distribution \[[@CR12], [@CR16]\]. Thus, the homogeneity index (HI) and four conformity indices (CI; these include the ICRU conformity index (CI~ICRU~), coverage index (CΔ), coverage index COV (CΔ~COV~), and conformation number (CN)) were calculated (Table [2](#Tab2){ref-type="table"}). These indices refer to the PTV volume, partial PTV volume covered by 95 % of prescribed isodose (PTV~*pi*~), and volume treated by 95 % of prescribed isodose (TV~*PI*~) \[[@CR16]\]. The HI characterizes dose homogeneity inside the PTV and is calculated using the near maximum (D2 %), near minimum (D98 %), and the mean dose (Dmean): D2 %--D98 % / Dmean (optimal at 0) \[[@CR12]\]. The CN provides complementary information about the irradiation of PTV and healthy tissues, and is calculated as PTV~*pi*~*/* PTV x PTV~*pi*~*/* TV~*PI*~; a value of 1 indicates optimal result \[[@CR17]\]. The CI~ICRU~ was described in the ICRU 62 report and is defined as the quotient TV~*PI*~*/* PTV (optimal at 1) \[[@CR18]\]. The CΔ quantifies the radiation exposure of the surrounding healthy tissue and is defined as TV~*PI*~-PTV~*pi*~*/* PTV (optimal at 0) \[[@CR19]\]. The CΔ~COV~ describes the coverage of the target volume by the prescribed isodose and is calculated as PTV~*pi*~*/* PTV; ideal PTV coverage is indicated by a value of 1 \[[@CR20]\].Table 2Averaged dosimetric values for PTV and conformal indexesHT\
Mean ± SDSW\
Mean ± SDRA\
Mean ± SDProtons\
Mean ± SDPairs with statistically significant differences (*P* = . \< 05)/Technique with best result (mean values)PTVPTV coverage (%)98.2 ± 1.498.6 ± 0.898.3 ± 0.899.6 ± 0.2Pr \> HT, Pr \> SW, Pr \> RA / Pr \> SW \> RA \> HTD2 % (%)103.3 ± 0.5102.5 ± 0.4102.4 ± 0.3102.5 ± 0.4RA \> HT, SW \> HT, Pr \> HT / RA \> SW = Pr \> HTD98 % (%)95.3 ± 1.995.5 ± 0.695.3 ± 0.696.7 ± 0.4Pr \> HT, Pr \> SW, Pr \> RA / Pr \> SW \> RA \> HTHomogeneity index, HI0.08 ± 0.020.07 ± 0.010.07 ± 0.010.06 ± 0.01Pr \> HT, Pr \> SW, Pr \> RA / Pr \> SW = RA \> HTConformation number, CN0.81 ± 0.040.89 ± 0.020.91 ± 0.030.88 ± 0.02SW \> HT, RA \> HT, RA \> SW, RA \> Pr, Pr \> HT / RA \> SW \> Pr \> HTICRU Conformity index, CI~ICRU~1.20 ± 0.11.09 ± 0.031.07 ± 0.041.13 ± 0.03SW \> HT, SW \> Pr, RA \> HT, RA \> Pr, Pr \> HT / RA \> SW \> Pr \> HTCoverage index, CΔ0.22 ± 0.10.11 ± 0.030.08 ± 0.030.13 ± 0.03RA \> HT, RA \> SW, RA \> Pr, SW \> HT / RA \> SW \> Pr \> HTCoverage index COV, CΔ~COV~0.98 ± 0.010.99 ± 0.010.98 ± 0.011.00 ± 0.0Pr \> HT, Pr \> SW, Pr \> RA / Pr \> SW \> RA = HT*Abbreviations*: *HT* helical tomotherapy; *SW* Sliding Window; *RA* Rapid Arc; *Pr* Protons; *SD* standard deviation; *\>* dosimetric superiority

A comparison of monitor units and treatment times could not be performed because the current implementation of monitor unit calculation in Eclipse Proton Planning is based on theoretical ideas and has not yet been verified by measurements due to a lack of experimental data (Proton Algorithm Reference Guide, Eclipse™ August 2013, Varian Medical Systems, Inc., Palo Alto).

In the statistical analyses, a non-parametric Wilcoxon signed-rank test was used to assess the differences between two techniques. The threshold for statistical significance was defined as *P* \< .05. All statistical analyses were performed using the SPSS software (IBM SPSS Statistics 22.0).

Treatment plans were created separately by three physicists.

Results {#Sec3}
=======

The dosimetric values for PTV and OAR were assessed from the patient-averaged dose-volume histogram (DVH) and are presented in detail in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}. The D98 % and D2 % did not significantly vary between the techniques. However, the HT showed inferior dose distribution within the PTV, with the largest interval between D98 % and D2 % values compared to SW, RA and IMPT. The IMPT provided significantly superior homogeneity values compared to HT, SW and RA (Table [2](#Tab2){ref-type="table"}). Comparison of the four CI, which describe the dose distribution within the PTV and the healthy tissue, demonstrated HT showed a tendency toward inferior conformation (Table [2](#Tab2){ref-type="table"}). A paired comparison analysis showed significantly improved CN for RA compared to HT (*P* = .001), SW (*P* = .005), and IMPT (*P* = .001). The IMPT demonstrated superior CN compared to HT (*P* = .001). The CI~ICRU~ value of 1.20 obtained by HT reflects a larger coverage volume by the treatment dose than the PTV itself. For RA was found significantly superior CI~ICRU~ in contrast to HT and IMPT (*P* = .001), and SW showed superior CI~ICRU~ compared to HT (*P* = .001) and IMPT (*P* = .002). The CΔ revealed that RA was significantly superior to all other techniques, and that SW was superior to HT and IMPT (*P* \< .05). IMPT showed significantly better CI~COV~ values than other modalities (*P* \< .05) (Table [2](#Tab2){ref-type="table"}).Table 3Averaged dosimetric values for organs at riskHT\
Mean ± SDSW\
Mean ± SDRA\
Mean ± SDProtons\
Mean ± SDPairs with statistically significant differences (*P* = . \< 05)/Technique with best result (mean values)Urinary Bladder V10 (%)42.0 ± 23.839.3 ± 23.346.8 ± 23.230.2 ± 18.5Pr \> HT, Pr \> SW, Pr \> RA, SW \> HT, SW \> RA / Pr \> SW \> HT \> RA V30 (%)26.2 ± 18.623.5 ± 16.427.0 ± 19.121.2 ± 14.7Pr \> HT, Pr \> SW, Pr \> RA, SW \> HT, SW \> RA / Pr \> SW \> HT \> RA V50 (%)16.8 ± 12.515.6 ± 11.617.0 ± 13.315.3 ± 11.5SW \> HT, SW \> RA, Pr \> RA, Pr \> HT / Pr \> SW \> HT \> RA V70 (%)6.0 ± 4.95.4 ± 4.86.4 ± 4.85.3 ± 4.7Pr \> SW, Pr \> RA, Pr \> HT / Pr \> SW \> HT \> RA Dmean (Gy)17.4 ± 10.115.8 ± 9.617.9 ± 10.113.3 ± 9.1Pr \> HT, Pr \> SW, Pr \> RA, SW \> HT, SW \> RA / Pr \> SW \> HT \> RA Dmax (Gy)82.5 ± 2.880.0 ± 2.880.9 ± 3.180.9 ± 1.7SW \> HT, RA \> HT, Pr \> HT / SW \> Pr \> RA \> HT D1ccm (Gy)76.3 ± 8.276.2 ± 6.376.3 ± 8.176.2 ± 6.0SW \> HT, Pr \> HT / Pr \> SW \> RA \> HTRectum V10 (%)59.1 ± 17.962.7 ± 16.669.0 ± 18.724.6 ± 9.2Pr \> HT, Pr \> SW, Pr \> RA, HT \> SW, HT \> RA, SW \> RA / Pr \> HT \> SW \> RA V30 (%)24.8 ± 7.632.8 ± 5.741.7 ± 11.315.7 ± 5.8Pr \> HT, Pr \> SW, Pr \> RA, HT \> SW, HT \> RA, SW \> RA / Pr \> HT \> SW \> RA V50 (%)12.8 ± 4.017.3 ± 2.523.5 ± 7.59.3 ± 3.8Pr \> HT, Pr \> SW, Pr \> RA, HT \> SW, HT \> RA, SW \> RA / Pr \> HT \> SW \> RA V70 (%)1.1 ± 0.71.5 ± 0.83.4 ± 1.81.0 ± 0.8Pr \> RA, Pr \> SW, HT \> SW, HT \> RA, SW \> RA / Pr \> HT \> SW \> RA Dmean (Gy)17.3 ± 3.920.3 ± 3.424.5 ± 5.39.0 ± 3.4Pr \> HT, Pr \> SW, Pr \> RA, HT \> SW, HT \> RA, SW \> RA / Pr \> HT \> SW \> RA Dmax (Gy)78.3 ± 1.875.9 ± 1.277.3 ± 1.576.4 ± 2.2Pr \> HT, Pr \> RA, SW \> HT, SW \> RA, SW \> Pr / SW \> Pr \> RA \> HT D1ccm (Gy)67.5 ± 4.168.9 ± 2.471.5 ± 2.565.9 ± 4.2HT \> SW, HT \> RA, SW \> RA, Pr \> HT, Pr \> SW, Pr \> RA / Pr \> HT \> SW \> RAFemoral head, right D1ccm (Gy)18.0 ± 2.932.0 ± 6.228.1 ± 5.335.2 ± 3.9HT \> SW, HT \> RA, HT \> Pr, RA \> SW, RA \> Pr / HT \> RA \> SW \> PrFemoral head, left D1ccm (Gy)18.1 ± 2.931.9 ± 5.126.6 ± 5.035.5 ± 2.5HT \> SW, HT \> RA, HT \> Pr, RA \> Pr, RA \> SW / HT \> RA \> SW \> Pr*Abbreviations*: *HT* helical tomotherapy; *SW* Sliding Window; *RA* Rapid Arc; *Pr* Protons; *PTV* planning target volume; *SD* standard deviation; *Dx (Gy)* dose (Gy) absorbed by certain percentage (%) or absolute volume (ccm) of the contoured structure; *Vx* percentage of organ volume exposed to certain radiation dose; *\>* dosimetric superiority

A greater difference in dose distribution between the techniques was found at the low-to-medium dose ranges compared to the higher doses (Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}). The patient-averaged DVH revealed IMPT had statistically superior rectum sparing at low-to-higher doses compared to all other techniques (V10--V70, *P* = \<.05), with the exception of HT at V70 (Fig. [3](#Fig3){ref-type="fig"}, Table [3](#Tab3){ref-type="table"}). Significantly lower rectum exposure was provided by HT compared to SW and RA at low-to-higher doses (V10--V70, *P* \< .05) (Fig. [3](#Fig3){ref-type="fig"}, Table [3](#Tab3){ref-type="table"}). A statistical difference in Dmean values was found in all tested pairs, with lower absolute values for protons and a maximum of absolute values for RA. Lowest Dmax value was achieved by SW, and D1ccm values revealed protons produced the lowest radiation exposure and RA produced the greatest coverage (Table [3](#Tab3){ref-type="table"}).Fig. 1Treatment plans for tomotherapy (HT), Sliding Window (SW), Rapid Arc (RA), and protons (IMPT). Representative dose distribution with V10 (yellow), V30 (green), V50 (blue), and V70 (orange) isodoses. The prostate is delineated in red, rectum in brown, urinary bladder in yellowFig. 2Patient-averaged dose-volume histograms. Dose-volume relationship of the planning target volume (**a**), rectal wall (**b**), and bladder wall (**c**) in the treatment plans of various IMRT techniquesFig. 3Pair-wise statistical dosimetric comparison between radiation techniques. The differences in OAR sparing are shown at dose ranges V10--V70, Dmean and Dmax for rectum and urinary bladder, and D1ccm for femoral heads. The urinary bladder is indicated in yellow, rectum in brown, femoral heads in green

The whole urinary bladder also experienced the best shielding using IMPT at lower-to-higher doses (V10--V70, *P* \< .05) (Fig. [3](#Fig3){ref-type="fig"}, Table [3](#Tab3){ref-type="table"}). SW demonstrated significantly lower bladder exposure in a wide dose spectrum than HT and RA (V10--V50, *P* \< .05) (Fig. [3](#Fig3){ref-type="fig"}, Table [3](#Tab3){ref-type="table"}). Dmean values were significantly different between all tested pairs, except for HT/RA, with lower absolute values for IMPT and higher absolute values for RA. Significantly lower Dmax values were gained for SW. D1ccm values revealed nearly the same bladder exposure for all techniques (Table [3](#Tab3){ref-type="table"}).

D1ccm values indicated femoral heads experienced the highest exposure from protons and superior sparing from HT (Table [3](#Tab3){ref-type="table"}). V50 revealed femoral heads received very small coverage volume (\<1 %) for all techniques.

Discussion {#Sec4}
==========

This study performed a statistical dosimetric comparison between different IMRT techniques using conventional fractionation to treat low-risk prostate cancer. IMRT was found to provide a conformal dose distribution, allowing dose escalation in the prostate and inferior OAR toxicity compared to 3-D conformal radiotherapy (3-D CRT) \[[@CR21]--[@CR24]\]. A dosimetric comparison between different IMRT techniques has already been performed in several series of studies \[[@CR1]--[@CR4], [@CR25]--[@CR32]\]. Tsai et al. found that HT provided superior conformity and OAR sparing compared to VMAT and static IMRT \[[@CR2]\]. Hermann et al. demonstrated comparable homogeneity, CN values and OAR dosimetric values between VMAT, SS and SW \[[@CR26]\]. The dosimetric comparison between static and rotational IMRT in this trial revealed superior rectum sparing by HT and superior bladder sparing by SW at low-to-higher doses (Table [3](#Tab3){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}). However, no accentuated priority for rectum sparing in HT plans or for bladder sparing in SW plans was made by the plans' assessment. In our opinion, the Tomo Planning System is more sensitive to dose constraints than the Eclipse planning system. This increased sensitivity can result in greater rectum sparing in HT plans while using the same dose objectives in the Eclipse planning system for SW and RA. In addition, the high sensitivity of the Tomo Planning System can result in larger SD values for homogeneity and the conformity indices in HT plans compared to other IMRT techniques, as shown in Table [2](#Tab2){ref-type="table"}. A higher radiation exposure for OAR at low doses was found for RA compared to HT and SW. Despite the use of two incomplete arcs intended to protect the rectum, RA demonstrated greater rectum exposure in a wide dose spectrum (Table [3](#Tab3){ref-type="table"}). However, most of the conformity values were statistically superior for RA compared to SW and HT. Thus, assuming same dose objectives for treatment planning, differences in dose distribution within PTV and OAR can be explained both by impact of radiation technique itself and by use of different dose calculation algorithms.

Superior sparing of OAR by protons is expected due to extremely steep dose gradients outside of the Bragg peak. As demonstrated by Vargas et al. for localized prostate carcinoma, protons provided improved rectum sparing at 10--80Gy and bladder sparing at 10--35Gy compared to the IMRT techniques \[[@CR5]\]. On the contrary, a comparable sparing of rectum, bladder and femoral heads for IMPT and VMAT techniques was observed by Georg et al. \[[@CR6]\]. In agreement with the results found by Schwarz et al., IMPT revealed similar homogeneity values and significantly inferior conformity values compared to HT. Rectum exposure for both techniques above 65Gy was equivalent, and superior sparing of bladder and penile bulb was obtained for protons in a wide dose spectrum \[[@CR7]\]. A recent SEER-Medicare based study observed a lower rate of gastrointestinal toxicity by IMRT-treated patients compared to proton-treated patients, and similar outcomes were observed for urinary toxicity and erectile dysfunction \[[@CR9]\]. Based on normal tissue complication probability (NTCP) estimates, Schwarz et al. demonstrated very similar probabilities of late gastrointestinal complications for HT and IMPT \[[@CR7]\]. Thus, the current data do not permit a definitive conclusion about the dosimetric superiority and therapy tolerance of protons compared to IMRT. In this study, IMPT showed an improved homogeneity value compared to the other techniques, and lower conformity values compared to SW and RA (Table [2](#Tab2){ref-type="table"}), although the planning software did not allow for a robust optimization of the proton therapy. In accordance with the findings of Vargas et al., the protons demonstrated statistically superior rectum and bladder sparing at low-to-higher doses (Table [3](#Tab3){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}). In the case of highly curative low-risk prostate carcinoma, it is critical both to perform homogeneous prostate coverage in order to achieve a long-term local tumor control, and to minimize the risk of chronic toxicities and secondary malignances. The steep dose gradient to the rectum and bladder, even at the lowest doses, leads to the assumption of decreased risk of secondary malignancy after proton treatment. However, the clinical relevance of the higher exposure of the femoral heads through the opposing right and left lateral beams used by protons is unknown. Thus, the incidence of late toxicity, including secondary malignancy, after proton treatment should be further evaluated in long-term trials.

The dose objectives for the rectum and urinary bladder met the criteria laid out by the QUANTEC reports \[[@CR14], [@CR15]\]. Current dose constraints are primarily generated from 3-D CRT datasets \[[@CR22]\]. The advanced IMRT techniques, including protons, all provide highly conformal dose distribution, performing superior OAR sparing than 3-D CRT. For this reason, dose objectives should be derived from the datasets of these advanced radiotherapy technologies.

For each radiation technique, a corresponding planning system is used to determinate dose calculation algorithms. Moreover, radiation plans can be optimized by individual modification of dose objectives for each treatment case. These arguments can diminish the relevance of the obtained results, despite the use of similar dose objectives in radiation planning. Thus, the selection criteria for dosimetric comparison of treatment plans should be further optimized.

De Meerleer et al. demonstrated that static IMRT plans had a superior ratio of tumor control probability (TCP)/normal tissue complication probabilities (NTCP) compared to 3-D CRT plans. As a result, IMRT techniques provide improved tumor control without a corresponding increase in radiation toxicities \[[@CR33]\]. The clinical relevance of dosimetric differences between various advanced IMRT techniques should be further analyzed in relation to NTCP parameters, including risk of secondary malignancy, as already described by Hall in several reviews \[[@CR34], [@CR35]\].

And finally, late-responding organs that have a low α/β ratio such as the prostate are more sensitive to high fraction doses \[[@CR36], [@CR37]\]. Several retrospective studies demonstrated the dosimetric feasibility, clinical outcomes, and local tumor control of hypofractionated radiotherapy in the treatment of localized prostate carcinoma \[[@CR38]--[@CR41]\]. Our ongoing research will focus on evaluating dose objectives for various advanced radiation techniques, including the Cyber Knife technique, in order to simultaneously provide homogeneous prostate coverage and conformal dose distribution through the delivery of a large fraction dose.

Conclusion {#Sec5}
==========

The major findings to emerge from this study are as follows: (i) All techniques revealed a homogeneous and high conformal dose distribution with more explicit differences at the low-to-medium dose ranges. At the dose above 50Gy all techniques demonstrated a steep dose gradient outside the PTV, implying a similar frequency and severity of acute toxicities. (ii) When using the same dose objectives during planning, IMPT revealed superior rectum and bladder sparing in a wide dose spectrum. This trend was more relevant at the low-to-medium doses. The superior OAR sparing by IMPT was concordant with results of Vargas et al, while did not match the results of Georg et al \[[@CR5], [@CR6]\]. In contrast to findings of Schwarz et al., IMPT revealed conformity values comparable to SW and RA techniques and even superior to HT \[[@CR7]\]. (iii) While the slight advantage in bladder sparing by SW can be explained by the use of different dose calculation algorithms during the treatment plan optimization process, the highly significant superior rectum sparring by HT can only be partially explained by the algorithm and is assumed to be a result of the HT treatment technique. Of course, the radiation plans can be further optimized by individual modification of dose objectives in dependence of treatment plan strategy.

Additional file {#Sec6}
===============

Additional file 1:Support strukture and dose objectives used for OAR. (DOCX 15 kb)
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